Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.11 USD
−15.73 M USD
0.00 USD
19.52 M
About Rein Therapeutics, Inc.
Sector
CEO
Brian J. Windsor
Headquarters
Austin
Website
Founded
2001
FIGI
BBG002454KR1
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RNTX is 2.20 USD — it has decreased by −10.20% in the past 24 hours. Watch Rein Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Rein Therapeutics, Inc. stocks are traded under the ticker RNTX.
RNTX stock has risen by 11.11% compared to the previous week, the month change is a 15.79% rise, over the last year Rein Therapeutics, Inc. has showed a −57.36% decrease.
We've gathered analysts' opinions on Rein Therapeutics, Inc. future price: according to them, RNTX price has a max estimate of 19.00 USD and a min estimate of 7.00 USD. Watch RNTX chart and read a more detailed Rein Therapeutics, Inc. stock forecast: see what analysts think of Rein Therapeutics, Inc. and suggest that you do with its stocks.
RNTX reached its all-time high on Oct 5, 2017 with the price of 6,192.00 USD, and its all-time low was 1.01 USD and was reached on Oct 31, 2023. View more price dynamics on RNTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RNTX stock is 15.88% volatile and has beta coefficient of 1.87. Track Rein Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Rein Therapeutics, Inc. there?
Today Rein Therapeutics, Inc. has the market capitalization of 47.66 M, it has decreased by −5.85% over the last week.
Yes, you can track Rein Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Rein Therapeutics, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
RNTX earnings for the last quarter are −0.27 USD per share, whereas the estimation was −0.24 USD resulting in a −10.20% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Rein Therapeutics, Inc. earnings.
Rein Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
RNTX net income for the last quarter is −5.85 M USD, while the quarter before that showed −8.94 M USD of net income which accounts for 34.61% change. Track more Rein Therapeutics, Inc. financial stats to get the full picture.
No, RNTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 24, 2025, the company has 15.00 employees. See our rating of the largest employees — is Rein Therapeutics, Inc. on this list?
Like other stocks, RNTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rein Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Rein Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Rein Therapeutics, Inc. stock shows the sell signal. See more of Rein Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.